US2006280813A1PendingUtilityA1
Pharmaceutical compositions containing bulbophyllum and their use for treating illnesses
Est. expiryApr 26, 2021(expired)· nominal 20-yr term from priority
Inventors:Michael Barthel
A61K 36/898A61P 9/00
59
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Described are pharmaceutical compositions containing Bulbophyllum , in particular compositions containing Bulbophyllum neilgherese , optionally in combination with suitable pharmaceutical excipients and carriers, as well as their use for treating illnesses, in particular illnesses of the cardiovascular system.
Claims
exact text as granted — not AI-modified1 - 11 . (canceled)
12 . A pharmaceutical composition containing Bulbophyllum neilgherense , optionally in combination with pharmaceutical acceptable excipients and/or carriers.
13 . A pharmaceutical composition according to claim 12 , wherein the Bulbophyllum neilgherense content per single dose is in the range of 1 ng to 1 mg.
14 . A pharmaceutical composition according to claim 12 , wherein the composition is processed into a form for epidural, peroral or topical administration.
15 . A pharmaceutical composition according to claim 12 , wherein the composition is processed into a form for injectable administration.
16 . A pharmaceutical composition according to claim 12 , wherein the composition is in the form of an alcoholic extract.
17 . A pharmaceutical composition according to claim 16 wherein the alcohol content is in the range of 81 to 100 percent by volume.
18 . A pharmaceutical composition according claim 12 for the treatment of cardiovascular disorders.
19 . A pharmaceutical composition according claim 18 , wherein the cardiovascular disorders comprise chest tightness, chest pressure, bradycardia, tachycardia, extrasystoles, arrhythmia, palpitation, atrial fibrillation, angina pectoris, stenosis of the coronary arteries, myocardial infarct, myocardial and septal hypertrophy, right ventricle cardiomegaly, primary pulmonary hypertension, hypertonia, peripheral acral cyanosis, dyspnea, and exertional dyspnea.
20 . A pharmaceutical composition for treating cardiovascular disorders comprising an effective amount of Bulbophyllum neilgherense , optionally in combination with pharmaceutically acceptable excipients and/or carriers.
21 . A pharmaceutical composition according to claim 20 , wherein the composition is in the form of an alcoholic extract.
22 . A pharmaceutical composition according to claim 21 , wherein the alcohol content is in the range of 81 to 100 percent by volume.
23 . A method for treating a patient suffering from cardiovascular disorders comprising administering to said patient the pharmaceutical composition according to claim 21 .
24 . The method according to claim 23 , wherein the pharmaceutical composition is administered as 1 to 3 daily doses over a period of 1 to 10 months.
25 . The method according to claim 23 , wherein the cardiovascular disorders comprise chest tightness, chest pressure, bradycardia, tachycardia, extrasystoles, arrhythmia, palpitation, atrial fibrillation, angina pectoris, stenosis of the coronary arteries, myocardial infarct, myocardial and septal hypertrophy, right ventricle cardiomegaly, primary pulmonary hypertension, hypertonia, peripheral acral cyanosis, dyspnea, and exertional dyspnea.Join the waitlist — get patent alerts
Track US2006280813A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.